Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

111
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
111
Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

197
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
197
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Expedited assessment for liver transplantation in patients with alcohol-associated liver disease using the Dallas consensus framework.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Lifetime management of aortic stenosis: A primer for the generalist.

The American journal of medicine·2026
Same author

Refining the definition of ACLF - keeping score and changing the game.

Journal of hepatology·2026
Same author

Comparative Prognostic Accuracy of Model for End-Stage Liver Disease Scores and the Freiburg Index of Post-Transjugular Intrahepatic Portosystemic Shunt Survival in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Procedure for Ascites or Gastroesophageal Bleeding: A Meta-Analysis of Time-Specific Mortality.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Electric field as a priming trigger reshaping redox network for synergistic perfluorooctanoic acid degradation and humus synthesis during aerobic composting.

Bioresource technology·2026
Same author

Differential survival benefit of curative versus non-curative intent treatment in a real-world cohort with early and intermediate-stage hepatocellular carcinoma.

Hepatology communications·2026

相关实验视频

Updated: Jun 15, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

根据MELD亚型的治疗意图生存率的变化:针对末期肝病创建的所有模型都不相同.

Craig Rosenstengle1, Marina Serper2, Sumeet K Asrani1

  • 1Baylor University Medical Center, Baylor Scott and White, Dallas, TX, United States.

Journal of hepatology
|August 24, 2024
PubMed
概括

对于等待肝移植 (LT) 的患者来说,由肌素驱动的高末期肝病模型 (MELD) 评分表明生存率较差. 这种MELD亚型,特别是在女性中,需要密切监测,并可能影响器官分配策略.

关键词:
性别差异的性别差异造成脏损伤的人.肝脏移植是什么?肝移植是什么?预测 预后 预测 预测

更多相关视频

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.5K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

231

相关实验视频

Last Updated: Jun 15, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.5K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

231

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 腎臟病學 (nephrology) 是一種醫學.
  • 移植手术 移植手术

背景情况:

  • 功能障碍显著影响等待肝移植 (LT) 的非补偿性肝硬化患者的预后.
  • 末期肝病模型 (MELD) 评分是这一群体死亡风险的关键预测指标.
  • 假设驱动MELD得分的特定成分 (肌素,胆红素或INR) 可能会影响患者的结果.

研究的目的:

  • 调查MELD得分的主要驱动因素是否会影响LT前后患者的治疗结果.
  • 为了比较不同MELD分数亚型的治疗意图 (ITT) 存活率.
  • 根据MELD得分组合,识别潜在的结果差异.

主要方法:

  • 分析了2016-2020年间在LT上列出的成年患者,不包括MELD例外情况和双器官移植.
  • 使用K-Means集群,根据占主导地位的MELD分数组件将患者分为MELD-Br,MELD-INR或MELD-Cr亚型.
  • 一年ITT生存率是主要的结局指标.

主要成果:

  • 已经确定了三种MELD亚型:MELD-Br (n=13,658),MELD-INR (n=13,809) 和MELD-Cr (n=12,412).这些亚型分别是MELD-Br (n=13,658),MELD-INR (n=13,809) 和MELD-Cr (n=12,412).
  • 一年ITT存活率为MELD-Br的78%,MELD-INR的75%,MELD-Cr的65%显著较低 (p<0.01).
  • 与其他亚型相比,MELD-Cr亚型在上市时表现出更高的MELD分数,在3个月内MELD下降幅度更大,等候名单死亡率增加,LT率较低,特别是在女性中.

结论:

  • 患有主要由肌素 (MELD-Cr) 驱动的MELD得分的患者,即使使用同等列表实践,一年ITT存活率也较低.
  • MELD亚型分类为评估动态死亡风险和指导器官分配提供了更细致的方法.
  • 作为MELD驱动因素的肌氨酸升高意味着预后较差,独立于整体MELD得分,突显了LT候选人的功能评估的重要性.